NCT06877065 Role of MRI Assessment in Fertility Sparing Treatment for Cervical Cancer at Staging and Follow-up and for Identification of Risk Factors for Aggressive Disease.
| NCT ID | NCT06877065 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Cervical Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-03-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to investigate the role of MRI, including DWI, in the staging and evaluation of response to fertility sparing treatment, including both primary surgery Protocol FeST-CC V.1.0 of November 10, 2023 Pag. 5 \| 23 (RT or CKC) or after NACT, followed by CKC, in patients with ECC (FIGO 2018 stage IB1- IIA1), desiring to preserve their fertility.
Eligibility Criteria
Inclusion Criteria: * Patients with cervical cancer FIGO stage up to IB2-IIA1 (T size \< 4 cm) wishing to preserve fertility treated at the Oncological Gynecology Unit of Foundation Policlinico Universitario Agostino Gemelli. * absence of nodal disease, * no menopausal status * wish to preserve fertility * refusal of radical treatment. * Patients who had a pre-treatment and post-treatment magnetic resonance imaging. * Availability of digital MR images and histopathological samples. Exclusion Criteria: * Patients aged under 18 years. * Neuroendocrine cervical tumours or other rare histology, such as glassy cells or clear cell carcinoma non-HPV related adenocarcinoma. * ongoing pregnancy at the time of diagnosis. * Patients without available MR images on digital media or with low quality images.
Contact & Investigator
Benedetta Gui
PRINCIPAL INVESTIGATOR
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Frequently Asked Questions
Who can join the NCT06877065 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06877065 currently recruiting?
Yes, NCT06877065 is actively recruiting participants. Contact the research team at benedetta.gui@policlinicogemelli.it for enrollment information.
Where is the NCT06877065 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06877065 clinical trial?
NCT06877065 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Benedetta Gui at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.